193 related articles for article (PubMed ID: 16286529)
1. High-sensitivity C-reactive protein in Japanese patients with type 2 diabetes.
Tajiri Y; Mimura K; Umeda F
Obes Res; 2005 Oct; 13(10):1810-6. PubMed ID: 16286529
[TBL] [Abstract][Full Text] [Related]
2. Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in Type 2 diabetic patients.
Tsunoda K; Arita M; Yukawa M; Ueyama M; Furuta M; Nakagawa T; Nanjo K; Sanke T
J Diabetes Complications; 2005; 19(3):123-7. PubMed ID: 15866055
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
[TBL] [Abstract][Full Text] [Related]
4. High sensitive C-reactive protein, adiponectin, and urine albumin excretion rate in Chinese coronary artery disease patients with different glucose tolerance status.
Gui MH; Hong J; Lü AK; Chen Y; Shen WF; Li XY; Ning G
Chin Med J (Engl); 2008 Dec; 121(24):2509-16. PubMed ID: 19187587
[TBL] [Abstract][Full Text] [Related]
5. Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets).
Shishido T; Konta T; Nishiyama S; Miyashita T; Miyamoto T; Takasaki S; Nitobe J; Watanabe T; Takeishi Y; Kubota I
Clin Exp Hypertens; 2011; 33(2):117-23. PubMed ID: 21269062
[TBL] [Abstract][Full Text] [Related]
6. Obesity, and not obstructive sleep apnea, is responsible for increased serum hs-CRP levels in patients with sleep-disordered breathing in Delhi.
Sharma SK; Mishra HK; Sharma H; Goel A; Sreenivas V; Gulati V; Tahir M
Sleep Med; 2008 Jan; 9(2):149-56. PubMed ID: 17638590
[TBL] [Abstract][Full Text] [Related]
7. High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome.
Aso Y; Wakabayashi S; Nakano T; Yamamoto R; Takebayashi K; Inukai T
Metabolism; 2006 Aug; 55(8):1014-21. PubMed ID: 16839835
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum C-reactive protein level and microalbuminuria in patients with type 2 diabetes mellitus.
Mojahedi MJ; Bonakdaran S; Hami M; Sheikhian MR; Shakeri MT; Aiatollahi H
Iran J Kidney Dis; 2009 Jan; 3(1):12-6. PubMed ID: 19377253
[TBL] [Abstract][Full Text] [Related]
9. The association between circulating inflammatory markers and metabolic syndrome in Korean rural adults.
Ryu SY; Kim KS; Park J; Kang MG; Han MA
J Prev Med Public Health; 2008 Nov; 41(6):413-8. PubMed ID: 19037171
[TBL] [Abstract][Full Text] [Related]
10. Meal testing and postprandial state of type 2 diabetic patients with metabolic syndrome.
Brădescu OM; Georgescu M; Ifrim S; Ioacără S; Ionescu-Tîrgovişte C
Rom J Intern Med; 2005; 43(1-2):97-113. PubMed ID: 16739870
[TBL] [Abstract][Full Text] [Related]
11. Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus.
Hernandez TL; Capell WH; Wolfe P; Gerard LA; Eckel RH
Am J Cardiol; 2006 Dec; 98(12):1656-9. PubMed ID: 17145229
[TBL] [Abstract][Full Text] [Related]
12. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis.
Mangge H; Schauenstein K; Stroedter L; Griesl A; Maerz W; Borkenstein M
Exp Clin Endocrinol Diabetes; 2004 Jul; 112(7):378-82. PubMed ID: 15239023
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory markers, insulin resistance and carotid intima-media thickness in North-Indian type 2 diabetic subjects.
Ahmad J; Ahmned F; Siddiqui MA; Khan AR; Katyal P; Hameed B; Ahmad I
J Assoc Physicians India; 2007 Oct; 55():693-9. PubMed ID: 18173021
[TBL] [Abstract][Full Text] [Related]
14. Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension.
Navarro-González JF; Mora C; Muros M; Jarque A; Herrera H; García J
J Hypertens; 2008 Nov; 26(11):2168-75. PubMed ID: 18854757
[TBL] [Abstract][Full Text] [Related]
15. Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical atherosclerosis.
Nishida M; Moriyama T; Ishii K; Takashima S; Yoshizaki K; Sugita Y; Yamauchi-Takihara K
Clin Chim Acta; 2007 Sep; 384(1-2):99-104. PubMed ID: 17618612
[TBL] [Abstract][Full Text] [Related]
16. Further inflammatory information on metabolic syndrome by adiponectin evaluation.
Matsushita K; Tamakoshi K; Yatsuya H; Wada K; Otsuka R; Takefuji S; Hotta Y; Kondo T; Murohara T; Toyoshima H
Int J Cardiol; 2008 Mar; 124(3):339-44. PubMed ID: 17433469
[TBL] [Abstract][Full Text] [Related]
17. The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus.
Alizadeh Dehnavi R; Beishuizen ED; van de Ree MA; Le Cessie S; Huisman MV; Kluft C; Princen HM; Tamsma JT
Eur J Intern Med; 2008 Mar; 19(2):115-21. PubMed ID: 18249307
[TBL] [Abstract][Full Text] [Related]
18. "Poor man's risk factor": correlation between high sensitivity C-reactive protein and socio-economic class in patients of acute coronary syndrome.
Sethi R; Puri A; Makhija A; Singhal A; Ahuja A; Mukerjee S; Dwivedi SK; Narain VS; Saran RK; Puri VK
Indian Heart J; 2008; 60(3):205-9. PubMed ID: 19240308
[TBL] [Abstract][Full Text] [Related]
19. Effects of lifestyle modifications on C-reactive protein: contribution of weight loss and improved aerobic capacity.
Jae SY; Fernhall B; Heffernan KS; Jeong M; Chun EM; Sung J; Lee SH; Lim YJ; Park WH
Metabolism; 2006 Jun; 55(6):825-31. PubMed ID: 16713444
[TBL] [Abstract][Full Text] [Related]
20. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes.
Mojiminiyi OA; Abdella NA; Al Arouj M; Ben Nakhi A
Int J Obes (Lond); 2007 Feb; 31(2):213-20. PubMed ID: 16755284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
